Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology

American Journal of Roentgenology

Volumn 204, Issue 5, 2015, Pages 919-932

  Howard, Stephanie A ^a   Rosenthal, Michael H ^a   Jagannathan, Jyothi P ^a   Krajewski, Katherine M ^a   Shinagare, Atul B ^a   Ramaiya, Nikhil H ^a   Tirumani, Sree Harsha ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alternate tumor response criteria; Anaplastic lymphoma kinase inhibitors; Epidermal growth factor receptor inhibitors; Immune modulators; Mammalian target of rapamycin inhibitors; Molecular targeted therapies

Indexed keywords

ABIRATERONE; AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANASTROZOLE; ANTINEOPLASTIC AGENT; B RAF KINASE; CERITINIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DABRAFENIB; ENZALUTAMIDE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; EXEMESTANE; IPILIMUMAB; K RAS PROTEIN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANITUMUMAB; PEMETREXED; TEMSIROLIMUS; TESTOLACTONE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VEMURAFENIB; ANGIOGENESIS INHIBITOR; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ALK GENE; BRAF GENE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; EGFR GENE; GENE MUTATION; GENE REARRANGEMENT; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NONANTIANGIOGENIC MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PARAMETERS; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; STANDARDIZED UPTAKE VALUE; STOMACH CANCER; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; NEOPLASMS; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84934324478     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.12876     Document Type: Review

References (91)

1. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759
2. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR 2010; 194:1470-1478
3. Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120:711-721
4. Howard SA, Krajewski KM, Thornton E, et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities-what radiologists should know. AJR 2012; 199:58-64
5. Abramson RG, Abramson VG, Chan E, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR 2013; 200:475-483
6. Nishino M, Jackman DM, Hatabu H, Janne PA, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol 2011; 18:424-436
7. Jackman DM, Janne PA. Does erlotinib improve symptoms in patients with lung cancer? Nat Clin Pract Oncol 2007; 4:146-147
8. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15:5267-5273
9. Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 1992; 69:1592-1599
10. Gazdar AF, Minna JD. Molecular detection of early lung cancer. J Natl Cancer Inst 1999; 91:299-301
11. Cadranel J, Ruppert AM, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant nonsmall-cell lung carcinoma. Crit Rev Oncol Hematol 2013; 88:477-493
12. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3342-3350
13. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327-3334
14. Golsteyn RM. Gefitinib does not increase survival in lung cancer patients. Drug Discov Today 2005; 10:381
15. Kaneda H, Yoshida T, Okamoto I. Molecularly targeted approaches herald a new era of nonsmall-cell lung cancer treatment. Cancer Manag Res 2013; 5:91-101
16. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703
17. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged nonsmall-cell lung cancer. N Engl J Med 2014; 370:1189-1197
18. Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 2013; 81:145-154
19. Tiseo M, Gelsomino F, Bartolotti M, et al. Anaplastic lymphoma kinase as a new target for the treatment of nonsmall-cell lung cancer. Expert Rev Anticancer Ther 2011; 11:1677-1687
20. Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012; 7:1722-1727
21. Nishino M, Cardarella S, Dahlberg SE, et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 79:283-288
22. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13:5150-5155
23. Park K, Tsai C-M, Ahn M-J, et al. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutationpositive non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(suppl):TPS7614
24. Browning ET, Weickhardt AJ, Camidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J Thorac Oncol 2013; 8:e21
25. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive nonsmall-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13:1011-1019
26. Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 2014; 271:6-27
27. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258:41-56
28. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multiinstitutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006; 52:135-140
29. Watanabe N, Nakahara Y, Taniguchi H, et al. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive nonsmall cell lung cancer and chronic interstitial pneumonia. Acta Oncol 2014; 53:158-160
30. Thornton E, Howard SA, Jagannathan J, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012; 85:1420-1426
31. Liu W, Makrauer FL, Qamar AA, Janne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5:917-920
32. O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALKpositive nonsmall cell lung cancer. Ann Pharmacother 2013; 47:189-197
33. Jerant AF, Johnson JT, Sheridan CD, Caf-frey TJ. Early detection and treatment of skin cancer. Am Fam Physician 2000; 62:357-368, 375-376, 381-382
34. Ramsay AG. Immune checkpoint blockade immunotherapy to activate antitumour T-cell immunity. Br J Haematol 2013; 162:313-325
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
36. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133
37. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420
38. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR 2011; 197:[web]W241-W246
39. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19:3936-3943
40. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31:1071-1077
41. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR 2013; 200:[web]W468-W474
42. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144
43. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013:857519
44. Lyall A, Vargas HA, Carvajal RD, Ulaner G. Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med 2012; 37:629-630
45. Gilardi L, Colandrea M, Vassallo S, Travaini LL, Paganelli G. Ipilimumab-induced immunomediated adverse events: possible pitfalls in 18F-FDG PET/CT interpretation. Clin Nucl Med 2014; 39:472-474
46. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239-1246
47. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
48. Muluneh B, Buie LW, Collichio F. Vemurafenibassociated pancreatitis: case report. Pharmacotherapy 2013; 33:e43-e44
49. Mahoney KM, Ackerman A, Cho DC, McDermott DF, Peters T, Atkins MB. Vemurafenib-induced cardiac tamponade: a rare but potentially lifethreatening complication. J Clin Oncol 2013; 31:e364-e366
50. Labianca R, Beretta GD, Mosconi S, Milesi L, Pessi MA. Colorectal cancer: screening. Ann Oncol 2005; 16(suppl 2):ii127-ii132
51. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30
52. Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res 2013; 5:387-400
53. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
54. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634
55. Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013; 31:3764-3775
56. Shablak A, Conn A. A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment. Target Oncol 2014; 9:177-180
57. Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese postmarketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012; 42:287-294
58. Yamada T, Moriwaki T, Matsuda K, et al. Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer. Onkologie 2013; 36:209-212
59. Yoon S, Hong YS, Park SH, Lee JL, Kim TW. Pneumatosis intestinalis after cetuximab-containing chemotherapy for colorectal cancer. Jpn J Clin Oncol 2011; 41:1225-1228
60. Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin North Am 2013; 27:715-736 [viii]
61. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006; 20:1029-1039; discussion, 1039-1040, 1042, 1048
62. Hagiwara M, Delea TE, Cong Z, Chung K. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer 2014; 22:103-113
63. Oster G, Lamerato L, Glass AG, et al. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 2014; 22:1363-1373
64. Agarwal S, Agarwal S, Gupta P, Agarwal PK, Agarwal G, Bansal A. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature. Acta Orthop Belg 2010; 76:567-571
65. Metzger-Filho O, Vora T, Awada A. Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy: current evidence and future trends. Expert Opin Investig Drugs 2010; 19(suppl 1):S31-S39
66. Polyak K, Metzger-Filho O. SnapShot: breast cancer. Cancer Cell 2012; 22:562-562.e1
67. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013; 19:5552-5556
68. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14:461-471
69. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-3533
70. Telli ML, Witteles RM. Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 2011; 9:243-249
71. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19:1613-1618
72. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743
73. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 2013; 19:6404-6418
74. Peroukides S, Makatsoris T, Koutras A, et al. Lapatinib-induced hepatitis: a case report. World J Gastroenterol 2011; 17:2349-2352
75. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010; 17:R305-R315
76. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197
77. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR 1984; 142:773-776
78. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17:4854-4861
79. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-1159
80. Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 2014; 6:39-51
81. Bennett LL, Ingason A. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Ann Pharmacother 2014; 48:530-537
82. Shinagare AB, Krajewski KM, Jagannathan JP, Ramaiya NH. Genitourinary imaging. Part Role of imaging in medical management of advanced renal cell carcinoma. AJR 2012; 199:[web] W554-W564
83. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 2011; 52:497-500
84. Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428-435
85. Mihaly Z, Sztupinszki Z, Surowiak P, Gyorffy B. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012; 12:857-872
86. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
87. Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I. Imaging in renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25:687-715
88. Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011; 59:856-862
89. Oudard S, Thiam R, Fournier LS, et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progressionfree survival in the RECORD-1 study. Eur J Cancer 2012; 48:1512-1518
90. Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48:1519-1524
91. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29:1750-1756